SteelPeak Wealth LLC Makes New Investment in Omnicell, Inc. (NASDAQ:OMCL)

SteelPeak Wealth LLC purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,271 shares of the company’s stock, valued at approximately $635,000.

A number of other hedge funds have also modified their holdings of the stock. GAMMA Investing LLC increased its position in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. KBC Group NV increased its holdings in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter. 1620 Investment Advisors Inc. raised its position in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after acquiring an additional 1,542 shares in the last quarter. Summit Global Investments acquired a new stake in Omnicell in the third quarter valued at approximately $221,000. Finally, QRG Capital Management Inc. bought a new stake in Omnicell in the third quarter worth approximately $231,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company reduced their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, Benchmark reissued a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Omnicell has an average rating of “Hold” and an average price target of $50.00.

Omnicell Trading Up 1.4 %

Shares of OMCL stock opened at $45.31 on Friday. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The firm’s fifty day simple moving average is $44.68 and its 200 day simple moving average is $42.64. The firm has a market capitalization of $2.10 billion, a P/E ratio of -116.18, a price-to-earnings-growth ratio of 29.73 and a beta of 0.78.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.